BACKGROUND & AIMS: Hereditary nonpolyposis colorectal cancer is associated with mismatch repair deficiency. Most predisposing mutations prevent the production of functional mismatch repair protein. Thus, when the wild-type copy is also inactivated, the cell becomes mismatch repair deficient, and this leads to a high degree of microsatellite instability in tumors. However, tumors linked to nontruncating mutations may display positive or partly positive immunohistochemical staining of the mutated protein and low or atypical microsatellite instability status, which suggests impaired functional activity but not a total lack of mismatch repair. We found human mutL homology (hMLH) 1 del616, one of the most widespread recurring mutations in hereditary nonpolyposis colorectal cancer, segregating in a large hereditary nonpolyposis colorectal cancer family. Because the predicted coding change is a deletion of only 1 amino acid, the pathogenicity of the mutation was evaluated. METHODS: Many analyses were performed to assess the pathogenicity of hMLH1 del616 and to study the expression and function of the mutated messenger RNA and protein. RESULTS: Genetic and immunohistochemical evidence supported hMLH1-linked cancer predisposition in this family. Microsatellite instability varied from low to high, and the hMLH1 protein was lost in 2 tumors but was partly detectable in 1 tumor. Whereas similar optimal amounts of mutated hMLH1 del616 and wild-type hMLH1 proteins were equally functional in an in vitro mismatch repair assay, the amount of in vivo-expressed hMLH1 del616 was much lower than the amount of wild-type protein; this suggests that the deletion imparts instability to the mutant protein. CONCLUSIONS: Our results suggest that the pathogenicity of hMLH1 del616 is not linked to nonfunctionality, but to shortage of the functional protein.
BACKGROUND & AIMS:Hereditary nonpolyposis colorectal cancer is associated with mismatch repair deficiency. Most predisposing mutations prevent the production of functional mismatch repair protein. Thus, when the wild-type copy is also inactivated, the cell becomes mismatch repair deficient, and this leads to a high degree of microsatellite instability in tumors. However, tumors linked to nontruncating mutations may display positive or partly positive immunohistochemical staining of the mutated protein and low or atypical microsatellite instability status, which suggests impaired functional activity but not a total lack of mismatch repair. We found human mutL homology (hMLH) 1 del616, one of the most widespread recurring mutations in hereditary nonpolyposis colorectal cancer, segregating in a large hereditary nonpolyposis colorectal cancer family. Because the predicted coding change is a deletion of only 1 amino acid, the pathogenicity of the mutation was evaluated. METHODS: Many analyses were performed to assess the pathogenicity of hMLH1 del616 and to study the expression and function of the mutated messenger RNA and protein. RESULTS: Genetic and immunohistochemical evidence supported hMLH1-linked cancer predisposition in this family. Microsatellite instability varied from low to high, and the hMLH1 protein was lost in 2 tumors but was partly detectable in 1 tumor. Whereas similar optimal amounts of mutated hMLH1 del616 and wild-type hMLH1 proteins were equally functional in an in vitro mismatch repair assay, the amount of in vivo-expressed hMLH1 del616 was much lower than the amount of wild-type protein; this suggests that the deletion imparts instability to the mutant protein. CONCLUSIONS: Our results suggest that the pathogenicity of hMLH1 del616 is not linked to nonfunctionality, but to shortage of the functional protein.
Authors: Lise Lotte Christensen; Reetta Kariola; Mari K Korhonen; Friedrik P Wikman; Lone Sunde; Anne-Marie Gerdes; Henrik Okkels; Carsten A Brandt; Inge Bernstein; Thomas V O Hansen; Rikke Hagemann-Madsen; Claus L Andersen; Minna Nyström; Torben F Ørntoft Journal: Fam Cancer Date: 2009-08-21 Impact factor: 2.375
Authors: Heather Hampel; Wendy L Frankel; Edward Martin; Mark Arnold; Karamjit Khanduja; Philip Kuebler; Mark Clendenning; Kaisa Sotamaa; Thomas Prior; Judith A Westman; Jenny Panescu; Dan Fix; Janet Lockman; Jennifer LaJeunesse; Ilene Comeras; Albert de la Chapelle Journal: J Clin Oncol Date: 2008-09-22 Impact factor: 44.544
Authors: Maria Simona Pino; Mari Mino-Kenudson; Bernadette Mandes Wildemore; Aniruddha Ganguly; Julie Batten; Isabella Sperduti; Anthony John Iafrate; Daniel C Chung Journal: J Mol Diagn Date: 2009-03-26 Impact factor: 5.568
Authors: Carlos A Vaccaro; Carlos Sarroca; Benedito Rossi; Francisco Lopez-Kostner; Mev Dominguez; Natalia Causada Calo; Raul Cutait; Adriana Della Valle; Lina Nuñez; Florencia Neffa; Karin Alvarez; Maria Laura Gonzalez; Pablo Kalfayan; Henry T Lynch; James Church Journal: Fam Cancer Date: 2016-07 Impact factor: 2.375
Authors: Jukka Kantelinen; Minttu Kansikas; Satu Candelin; Heather Hampel; Betsy Smith; Liisa Holm; Reetta Kariola; Minna Nyström Journal: Hum Mutat Date: 2012-06-11 Impact factor: 4.878